Immediate Surgery Might Be a Better Option for Subcapsular Thyroid Microcarcinomas

Jun Jiang and Hui Lu

Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, China

Correspondence should be addressed to Hui Lu; luhui@jsph.org.cn

Received 17 December 2018; Accepted 25 March 2019; Published 3 April 2019

Academic Editor: Lodovico Rosato

Copyright © 2019 Jun Jiang and Hui Lu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

For high-risk papillary thyroid microcarcinomas (PTMCs), immediate surgery is recommended. This study aimed to evaluate the location of PTMCs in the thyroid lobe and determine whether location is associated with an aggressive biology and the necessity of immediate surgery. This retrospective study included 288 patients who underwent initial surgery for PTMC. Clinical data were extracted. Subcapsular thyroid microcarcinomas (STMs) and nonsubcapsular thyroid microcarcinomas (NSTMs), distinguished by ultrasound, were compared in terms of tumour size, extrathyroidal extension, cervical lymph node metastasis, and multifocality. The preoperative ultrasound features predictive of recurrent laryngeal nerve (RLN) involvement were assessed. There were no statistical differences in tumour size \((P = 0.985)\), multifocality \((P = 0.866)\), lymph node metastases to the central compartment \((P = 0.154)\), or lateral lymph node metastases \((P = 0.929)\) between STM and NSTM groups. Macroscopic extrathyroidal extension was exclusively found in the STM group. For assessing RLN involvement, the sensitivity, specificity, and positive predictive value of the presence of an abnormal thyroid capsule margin between the STM and the presumed RLN course, assessed on preoperative ultrasonography images, were 100%, 43.3%, and 43.3%, respectively. Immediate surgery appears to be a better option than conservative treatment for these high-risk STM patients.

1. Introduction

Papillary thyroid carcinoma (PTC) is the most common well-differentiated thyroid carcinoma. The majority of newly diagnosed PTCs are papillary thyroid microcarcinomas (PTMCs), defined as PTC ≤ 1 cm in maximal diameter [1, 2], primarily due to the routine use of high-resolution ultrasonography in regular health examinations [3]. Many researchers have recommended conservative management for low-risk PTMCs due to their slow growth [4]. It is worth noting that the definition of PTMC is PTC with a maximal diameter of ≤1 cm, regardless of its biological behaviour. PTMCs with cervical lymph node metastasis (LNM) and locoregional invasiveness or recurrence are frequently detected [5]. Less frequently, PTMCs with distant metastases are reported [6]. It is reasonable to identify and treat high-risk PTMCs with aggressive features. Nevertheless, PTMCs located close to the capsular area, identified by radiological investigations, should also be considered serious. Subcapsular thyroid microcarcinomas (STMs) can easily progress to extrathyroidal extension (ETE), possibly invading important surrounding tissues such as the trachea, recurrent laryngeal nerve (RLN), or carotid artery; however, they are not necessarily associated with biological aggressiveness. For these STMs, individualised treatment strategies including active surveillance, lobectomy, or total thyroidectomy with or without cervical lymph node dissection should be carefully considered [2, 7].

The purpose of this study was to investigate the clinical and ultrasonography characteristics of STMs and to determine whether they are associated with aggressive behaviour.

2. Materials and Methods

2.1. Patient Selection. Patients with PTMC who underwent initial thyroid surgery between June 2017 and June 2018 were included in this retrospective, single-centre study. All these patients were diagnosed as PTMC on ultrasonography-guided fine needle aspiration biopsy (FNAB).
Table 1: Characteristics of the study subjects.

|                        | STM (N = 93) | NSTM (N = 195) | P value |
|------------------------|-------------|----------------|---------|
| Age (year)             | 43 (35 – 42)| 41 (33 – 49)   | 0.267⁴  |
| Male                   | 23 (24.7%)  | 45 (23.1%)     | 0.757⁵  |
| Size (cm)              | 0.7 (0.5 - 0.8)| 0.7 (0.6 - 0.8)| 0.985⁴  |
| Microscopic-ETE        | 67 (72.0%)  | 0              | ≤ 0.001³ |
| Macroscopic-ETE        | 42 (45.2%)  | 0              | ≤ 0.001³ |
| Sternothyroid muscle   | 22          | 0              | ≤ 0.001³ |
| Trachea                | 6           | 0              | 0.001³  |
| RLN                    | 15          | 0              | ≤ 0.001³ |
| Lymph node metastasis  |             |                |         |
| N1a                    | 37 (39.8%)  | 61 (31.3%)     | 0.154⁶  |
| N1b                    | 5 (5.4%)    | 10 (5.1%)      | 0.929⁶  |
| Tumor multifocality    | 16 (17.2%)  | 32 (16.4%)     | 0.866⁶  |
| Bilateral lesions      | 12 (12.9%)  | 36 (18.3%)     | 0.237⁶  |
| Hashimoto’s thyroiditis| 24 (25.8%)  | 59 (30.3%)     | 0.436⁶  |

STM, subcapsular thyroid microcarcinoma; NSTM, nonsubcapsular thyroid microcarcinoma; ETE, extrathyroidal extension; RLN, recurrent laryngeal nerve; N1a, metastases to central cervical lymph nodes; N1b, metastases to lateral neck lymph nodes.

Continuous data are presented as the median with interquartile ranges.

a Determined using the Wilcoxon signed-rank test.
b Determined using the Chi-square test.
c Determined using the Fisher’s exact test.

PTMC patients without clinical lymph node or distant metastasis, who were managed with observation, were excluded. Patients with PTMC of the thyroid isthmus or incidentally detected PTMC during surgery for benign thyroid disease were also excluded.

2.2. Clinical Data. The medical records of all patients with pathologically confirmed PTMC were reviewed. Individualised surgery strategies were based on preoperative sonographic evaluation, intraoperative inspection, and frozen section. All patients underwent routine prophylactic central neck dissection. Therapeutic lateral cervical neck dissection was indicated in patients with clinically apparent lateral cervical LNM. Preoperative laryngoscopy was routinely performed in all patients. Postoperative laryngoscopy was performed in symptomatic patients with voice change on postoperative day 1.

2.3. Preoperative Imaging. Representative transverse and longitudinal ultrasonography images in the database were reviewed by an expert ultrasonography radiologist and a surgeon. STM was defined as a nodule bordering or already penetrating the thyroid capsule, or even with obvious ETE. If it did not meet these criteria, intrathyroidal microcarcinoma was defined as a nonsubcapsular thyroid microcarcinoma (NSTM) (Figure 1). Some researchers have previously noted that PTC along the RLN course may be more likely to invade the RLN. Whether STM invades the RLN is judged according to the presence of a normal margin of the thyroid capsule between the STM and the presumed location of the RLN on ultrasound images [8]. The possibility of local invasion by STM was also investigated in this study.

2.4. Statistical Analyses. Comparisons between two groups were made using Wilcoxon signed-rank test, chi-square test, or Fisher’s exact test. The sensitivity, specificity, positive predictive value, and negative predictive value were evaluated for the predictive value of sonographic ETE features in RLN invasion. Any P-value ≤ 0.05 was considered to indicate a statistically significant difference.

3. Results

3.1. Baseline Characteristics of the Study Population. In the current study, initial surgery was performed on a total of 288 patients with PTMC, among which 93 patients had STMs and 195 had NSTMs. The clinical characteristics of STMs and NSTMs are presented in Table 1. STMs accounted for 93 (32.3%) of 288 PTMCs. Among these STMs, 39 were located close to the anterolateral surface (Figures 1(b) and 1(c)) of the thyroid lobe (22 in the right lobe and 17 in the left lobe), 43 were located close to the anterolateral surface (Figure 1(d)) of the thyroid lobe (20 in the right lobe and 23 in the left lobe), and 11 were located close to the medial surface (Figure 1(e)) of the thyroid lobe (six in the right lobe and five in the left lobe). In both groups, the majority of PTMC patients were relatively young (under 50 years old) women. There were no cases of distant metastases in these included patients. The median tumour size revealed by histological analysis was 0.7 cm (interquartile range 0.5–0.8) in the STM group and 0.7 cm (interquartile range 0.6–0.8) in the NSTM group.
group. There was no statistical difference in tumour size between the two groups (Wilcoxon signed-rank test, \( P = 0.985 \)).

3.2. Association between Subcapsular Location and Extrathyroidal Extension. It is still unknown whether STMs are associated with aggressive biological behaviour, indicated by characteristics including ETE and cervical LNM [5]. In this study, STMs showed a significantly higher proportion of microscopic ETE (67/93, 72%) than NSTMs (0/195, 0%; Figure 1(f)). Of these STMs with microscopic ETE, 35 lesions were located in the right thyroid lobe, among which 14, 17, and 4 were located dorsally, anterolaterally, and medially to the thyroid capsule, respectively. There were 32 microscopic ETE lesions located in the left thyroid lobe, among which 16, 12, and 4 were located dorsally, anterolaterally, and medially to the thyroid capsule, respectively.

Gross ETE (45.2%) in STMs was confirmed by intraoperative inspection (Fisher’s exact test, \( P < 0.001 \)). The sternothyroid muscle was invaded in 22 STMs (12 in the right lobe and 10 in the left lobe), and the trachea was invaded in six STMs (three in each lobe). The RLN was involved in 15 patients (six in the right lobe and nine in the left lobe), in which preoperative laryngoscopy found no vocal cord paralysis. In the right lobe, one STM measuring 5 mm in diameter located medial to the surface of the thyroid lobe simultaneously invaded the trachea and RLN near the Berry's ligament (Figure 1(e)). One STM measuring 6 mm in diameter located medial to the trachea invaded the entry point of the RLN to the larynx without invading the trachea (Figures 2(a) and 2(b)).

3.3. Predictive Factors for Extrathyroidal Extension to the Recurrent Laryngeal Nerve. In the 43 STMs located close to the dorsal surface of the thyroid lobe, histological analysis identified 30 microscopic ETE lesions which lacked the normal thyroid capsule margin between the STM and the presumed RLN course on ultrasonography images (Figures 2(c) and 2(d)). Thirteen out of these 30 STMs with microscopic ETE showed gross invasion of the RLN (five in the right lobe and eight in the left lobe). These 13 STMs with RLN involvement presented a significantly larger tumour diameter (0.8 ± 0.2 cm) than the remaining 17 STMs without RLN invasion (0.5 ± 0.2 cm; Wilcoxon signed-rank test, \( P = 0.0003 \)). Regarding ultrasonography features, the sensitivity, specificity, positive predictive value, and negative predictive value of an abnormal margin for RLN involvement were 100%, 43.3%, 43.3%, and 100%, respectively.

In most cases involving the RLN, the RLN could be easily isolated from the thyroid capsule as the tumour foci were merely in close contact with the RLN, with minimal invasion. Some STMs without dense adhesion with the RLN could be isolated by sharp dissection using mosquito forceps or scissors in order to leave as little remaining tumour as possible. No cases required partial dissection of the RLN. However, 3 out of 13 patients developed transient unilateral vocal cord paralysis, which recovered in 2–4 months.
3.4. Association between Subcapsular Location and Aggressive Biological Behaviour. Routine central compartment lymph node clearance in all included patients revealed no significant differences in the incidence of LNM between the STM group (37/93) and the NSTM group (61/195; chi-square test, \(P = 0.154\)). With respect to the incidence of lateral cervical LNM, there were also no significant differences between the STM group (5/93) and the NSTM group (10/195; chi-square test, \(P = 0.929\); Table 1). In the NSTM group, a case of lymph node skip metastasis was detected.

Tumour multifocality might suggest a high-grade malignancy, which is associated with a higher risk of persistent or recurrent disease [9, 10]. In the included patients, there were no significant differences in multifocality between the STM (16/93) and NSTM (32/195) groups (chi-square test, \(P = 0.866\)). Twelve (12.9%) of the 93 patients in the STM group and 36 (18.5%) of the 195 patients in the NSTM group had bilateral disease, and there were also no significant differences in the bilateral distribution of tumour foci between the two groups (chi-square test, \(P = 0.237\)).

Some reports argue that PTC patients with coexistent Hashimoto’s thyroiditis (HT) might have less aggressive disease and better clinical outcomes [11]. Thus, the proportion of patients with coexisting HT may influence the comparison of the biological behaviour between the two groups in this study. Here, we found no significant differences in the proportion of patients with coexisting HT between the STM (24/93, 25.8%) and NSTM (59/195, 30.3%) groups (chi-square test, \(P = 0.436\)).

4. Discussion

In the current study, our data indicate that STMs have a unique tendency to penetrate the thyroid capsule and invade the surrounding tissue. However, the most plausible explanation for this phenomenon is that these STMs are peripherally located, as it did not seem to be associated with an aggressive biology.

PTMCs exhibit a broad range of biological behaviours, ranging from passive to very aggressive [12, 13]. Accordingly, individualised strategies should be used to treat PTMC [2]. Nonoperative active surveillance of PTMCS is now an accepted alternative to immediate surgery [2, 14, 15]. However, Chinese patients’ willingness plays an important role in treatment decision-making; thus FNAB and subsequent surgery were performed at the patient’s request in many PTMC patients for fear of the potential aggressiveness of PTMC in China regardless of recommendations from some guidelines or expert consensus [15–18]. There is also no denying that very limited information is available on preoperative precise prediction of biological behaviour even with the aid of FNA-based cytological and molecular detection [3, 19–22]. Controversy still continues regarding the best treatment for PTMC patients among thyroid surgeons in
It is difficult to remove tumour completely without eventumourswitha5mmdiametercaninvadetheRLNand Berry'sligamentortheentrypointoftheRLNintothelarynx, closetotheBerry'sligamentwereathigherriskforRLNand radioiodinetreatmentbasedonourexperience.

Local recurrence or mortality with the aid of postoperative preoperative normal vocal cord function did not increase along the course of the preserved RLN in patients with invasion from close contact or compression, thus avoiding the RLN during surgery is useful to differentiate tumour our experience, the precise identification and exposure of be easily isolated from PTMCs by sharp dissection. In Fortunately, our data showed that the "invaded" RLN could did not invade the RLN. Different from the report by Ito et al. [8] between STM and NSTM groups, because these uncommon pathologicsubtypeswerenotroutinelyanalysedandreported by ultrasound measurement. The left RLN seems to be more vulnerable than the contralateral side. This can be partly explained by anatomy, as the left RLN is in a more typical medial tracheoesophageal groove position compared to the right RLN [29]. Thus, STMs, especially relatively larger ones, are not suitable for conservative treatment. In comparison of previous reports [12, 14, 30], our study further elucidated what kind of PTMCs were not suitable for active surveillance.

In our study, whether STMs involved the RLN was judged by distortion or a long interface between the STM and the thyroid capsule on the ultrasonography images [2]. Here, the sensitivity and specificity values for predicting RLN involvement based on the presence of an abnormal margin of the thyroid capsule on the sonography image were 100% and 43.3%, respectively. However, this result should be interpreted with caution, as the ultrasonography images assessed in this retrospective study were not dynamic, serially recorded, and user-dependent. This represents one of the limitations of this study. Real-time ultrasound, providing complete information, would be more reliable to confirm the presence of an abnormal margin. Moreover, variations in the course of RLN and the point or plane of STMs penetration should also be considered when evaluating the possibility of RLN involvement using the index of an “abnormal rim” by the previous report. Therefore, it is still difficult to judge RLN invasion solely by the presence of an “abnormal rim.” Another limitation of the current study is that we did not explore the specific histological subtypes of PTMC (e.g., tall cell, insular, columnar cell, and diffuse sclerosing carcinomas), which may behave more aggressively [31], between STM and NSTM groups, because these uncommon pathologic subtypes were not routinely analysed and reported in our pathology department.

5. Conclusions
In summary, STMs may not be associated with aggressive biological characteristics, but instead with a high risk of ETE to important adjacent structures such as the RLN, trachea, and strap muscles. Given the good prognosis of PTMC, lowering the morbidity and improving the patient’s quality of life are necessary considerations of thyroid surgeons. High-risk STM patients are not candidates for conservative treatment, and active surgery appears to be a safer and better option.

Data Availability
Data supporting this research article are available upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
The authors thank Dr. WT Ma for her excellent aid in ultrasound image analysis.

References
[1] T. Carling and R. Udelsman, “Thyroid cancer,” Annual Review of Medicine, vol. 65, pp. 125–137, 2014.
[2] A. Miyauchi, Y. Ito, and H. Oda, “Insights into the management of papillary microcarcinoma of the thyroid,” Thyroid, vol. 28, no. 1, pp. 23–31, 2018.
[3] M. E. Cabanillas, D. G. McFadden, and C. Durante, “Thyroid cancer,” The Lancet, vol. 388, no. 10061, pp. 2783–2795, 2016.
[4] S. Lebouleux, R. M. Tuttle, F. Pacini, and M. Schlumberger, “Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?” The Lancet Diabetes & Endocrinology, vol. 4, no. 11, pp. 933–942, 2016.
[5] M. J. Jeon, M. S. Chung, H. Kwon et al., “Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis,” Clinical Endocrinology, vol. 86, no. 6, pp. 845–851, 2017.
[6] M. J. Jeon, W. G. Kim, Y. M. Choi et al., “Features predictive of distant metastasis in papillary thyroid microcarcinomas,” Thyroid, vol. 26, no. 1, pp. 161–168, 2016.
[7] C. S. Grant, “Papillary thyroid cancer: Strategies for optimal individualized surgical management,” Clinical Therapeutics, vol. 36, no. 7, pp. 1117–1126, 2014.
[8] Y. Ito, A. Miyauchi, H. Oda, K. Kobayashi, M. Kihara, and A. Miya, “Revisiting low-risk thyroid papillary microcarcinomas resected without observation: was immediate surgery necessary?” World Journal of Surgery, vol. 40, no. 3, pp. 523–528, 2016.
[9] K. R. Joseph, S. Edirianmane, and G. D. Eslick, “Multifocality as a prognostic factor in thyroid cancer: a meta-analysis,” International Journal of Surgery, vol. 50, pp. 121–125, 2018.
[10] Y. K. So, M. W. Kim, and Y. I. Son, “Multifocality and bilaterality of papillary thyroid microcarcinoma,” Clinical and Experimental Otorhinolaryngology, vol. 8, no. 2, pp. 174–178, 2015.
[11] E. Song, M. J. Jeon, S. Park et al., “Influence of coexistent Hashimoto’s thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma,” Clinical Endocrinology, vol. 88, no. 1, pp. 123–128, 2018.
[12] Y. Ito, A. Miyauchi, and H. Oda, “Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials,” European Journal of Surgical Oncology, vol. 44, no. 3, pp. 307–315, 2018.
[13] G. Ardito, L. Revelli, E. Giustozzi et al., “Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy,” Clinical Nuclear Medicine, vol. 38, no. 1, pp. 25–28, 2013.
[14] J. P. Brito, Y. Ito, A. Miyauchi, and R. M. Tuttle, “A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma,” Thyroid, vol. 26, no. 1, pp. 144–149, 2016.
[15] B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016.
[16] F. N. Tessler, W. D. Middleton, E. G. Grant et al., “ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee,” Journal of the American College of Radiology, vol. 14, no. 5, pp. 587–595, 2017.
[17] M. Gao, M. Ge, Q. Ji et al., “2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma,” Cancer Biology & Medicine, vol. 14, no. 3, pp. 203–211, 2017.
[18] R. M. Tuttle, “Controversial issues in thyroid cancer management,” Journal of Nuclear Medicine, vol. 59, no. 8, pp. 1187–1194, 2018.
[19] S. M. Ferrari, P. Fallahi, I. Ruffilli et al., “Molecular testing in the diagnosis of differentiated thyroid carcinomas,” Gland Surgery, vol. 7, no. S1, pp. S19–S29, 2018.
[20] D. N. Poller and S. Glaysher, “Molecular pathology and thyroid FNA,” Cytopathology, vol. 28, no. 6, pp. 475–481, 2017.
[21] A. Colanta, O. Lin, L. Tafe et al., “BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis,” Acta Cytologica, vol. 55, no. 6, pp. 563–569, 2011.
[22] F. Galuppinii, G. Pennelli, F. Vianello et al., “BRAF analysis before surgery for papillary thyroid carcinoma: Correlation with clinicopathological features and prognosis in a single-institution prospective experience,” Clinical Chemistry and Laboratory Medicine, vol. 54, no. 9, pp. 1531–1539, 2016.
[23] M. G. Castagna, R. Forleo, F. Maino et al., “Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumors,” Journal of Endocrinological Investigation, vol. 41, no. 9, pp. 1029–1035, 2018.
[24] C. G. Woo, C. O. Sung, Y. M. Choi et al., “Clinicopathological significance of minimal extrathyroidal extension in solitary papillary thyroid carcinomas,” Annals of Surgical Oncology, vol. 22, Suppl. 3, pp. 728–733, 2015.
[25] C. Casella, S. Ministrini, A. Galani, F. Mastriale, C. Cappelli, and N. Portolani, “The new TNM staging system for thyroid cancer and the risk of disease downstaging,” Frontiers in Endocrinology, vol. 9, p. 541, 2018.
[26] B.-Y. Kim, J.-E. Choi, E. Lee et al., “Prognostic factors for recurrence of locally advanced differentiated thyroid cancer,” Journal of Surgical Oncology, vol. 116, no. 7, pp. 877–883, 2017.
[27] T. Nishida, K. Nakao, M. Hamaji, W. Kamlike, K. Kurozumi, and H. Matsuda, “Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer,” Annals of Surgery, vol. 226, no. 1, pp. 85–91, 1997.
[28] M. L. Shindo, S. M. Caruana, E. Kandil et al., “Management of invasive well-differentiated thyroid cancer: an american head and neck society consensus statement. AHNS consensus statement,” Head & Neck, vol. 36, no. 10, pp. 1379–1390, 2014.
[29] R. E. M. Bowden, “The surgical anatomy of the recurrent laryngeal nerve,” British Journal of Surgery, vol. 43, no. 178, pp. 153–163, 1955.
[30] R. M. Tuttle, L. Zhang, and A. Shaha, “A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management,” Expert Review of Endocrinology & Metabolism, vol. 13, no. 2, pp. 77–85, 2018.
[31] M. Sywak, J. L. Pasieka, and T. Ogilvie, “A review of thyroid cancer with intermediate differentiation,” Journal of Surgical Oncology, vol. 86, no. 1, pp. 44–54, 2004.